Congenital Diaphragmatic Hernia Drugs Market Report 2026

Congenital Diaphragmatic Hernia Drugs Market Overview

• Congenital Diaphragmatic Hernia Drugs market size has reached to $4.69 billion in 2025 • Expected to grow to $6.81 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Elevated Birth Defect Rates Fuel Growth In The Congenital Diaphragmatic Hernia Drug Market • North America was the largest region in 2025.

What Is Covered Under Congenital Diaphragmatic Hernia Drugs Market?

Congenital diaphragmatic hernia (CDH) is a rare condition that occurs when there is a hole in the diaphragm, the muscle that separates the chest from the abdomen. Congenital diaphragmatic hernia (CDH) drugs refer to the medications used in the treatment of Congenital diaphragmatic hernia and help reduce the severity of the disease and manage the symptoms and complications associated with the disease. The main types of congenital diaphragmatic hernia drugs are posterolateral bochdalek hernia, anterior morgagni hernia and hiatal hernia. Posterolateral bochdalek hernia is a type of congenital diaphragmatic hernia, where an opening or defect in the back part of the diaphragm allows abdominal organs to move into the chest cavity. The various types of treatment include extracorporeal membrane oxygenation and others through various diagnoses such as prenatal and postnatal. These are used by various end-users such as hospitals, homecare, specialty clinics and others.

What Is The Congenital Diaphragmatic Hernia Drugs Market Growth Forecast?

The congenital diaphragmatic hernia drugs market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to growth in precision medicine, increasing investment in neonatal care, rising awareness of early intervention, advancements in drug delivery technologies, expansion of healthcare infrastructure in emerging regions. Major trends in the forecast period include advanced neonatal care medications, minimally invasive treatment approaches, personalized drug formulations, early diagnosis and intervention therapies, multi-modal symptom management.

Global Congenital Diaphragmatic Hernia Drugs Market Segmentation

1) By Type: Posterolateral Bochdalek Hernia, Anterior Morgagni Hernia, Hiatal Hernia 2) By Treatment: Extracorporeal Membrane Oxygenation, Other Treatments 3) By Diagnosis: Prenatal, Postnatal 4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Posterolateral Bochdalek Hernia: Surgical Interventions, Medications for Symptoms 2) By Anterior Morgagni Hernia: Medications for Symptoms 3) By Hiatal Hernia: Surgical Interventions, Medications

What Are The Drivers Of The Congenital Diaphragmatic Hernia Drugs Market?

The rising birth defects rate is expected to propel the growth of the congenital diaphragmatic hernia drug market. Birth defects refer to structural or functional abnormalities present at birth that can affect the baby's overall health and development. The treatment for congenital diaphragmatic hernia provides prenatal screening, genetic counseling and targeted therapies that lower the occurrence of birth defects due to congenital diaphragmatic hernia and improve the potential for early intervention and personalized care, enhancing the overall well-being and quality of life of affected individuals. For instance, in March 2023, according to the World Health Organization (WHO), a US-based intergovernmental organization, annually, approximately 8 million infants are born with birth defects, with low- and middle-income nations accounting for 9 out of 10 significant problems. Further, an estimated 240,000 newborns die worldwide within 28 days of birth each year due to congenital disorders. Therefore, the rising birth defect rate drives the congenital diaphragmatic hernia drug industry. The rising clinical trial in pharmaceutical is expected to propel the growth of the congenital diaphragmatic hernia drug market going forward. A clinical trial in pharmaceuticals is a research study that tests new drugs or treatments in humans to evaluate their safety and effectiveness. Clinical trials in pharmaceuticals are increasing due to the rising need for innovative and more effective therapies. Congenital diaphragmatic hernia drugs are evaluated in clinical trials to assess their safety and effectiveness in improving outcomes for affected newborns. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the total number of clinical trials initiated in the UK rose from 411 in 2022 to 426 in 2023. Therefore, the rising clinical trial in pharmaceutical is driving the growth of the congenital diaphragmatic hernia drug industry.

Key Players In The Global Congenital Diaphragmatic Hernia Drugs Market

Major companies operating in the congenital diaphragmatic hernia drugs market are Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Bayer AG, Mallinckrodt Pharmaceuticals, Boehringer Ingelheim International GmbH, AbbVie Inc., Sanofi SA, Johnson & Johnson, United Therapeutics Corporation, Bristol‑Myers Squibb Company, Aurobindo Pharma Ltd, Cipla Inc., Lupin Ltd., Zydus Lifesciences Ltd., Fresenius Kabi.

What Are Latest Mergers And Acquisitions In The Congenital Diaphragmatic Hernia Drugs Market?

In May 2023, Juno Pharmaceuticals, a Canada-based pharmaceutical company, acquired Omega Laboratories Inc. for an undisclosed amount. This acquisition establishes Juno as the largest specialty generic injectable business in Canada, enhancing its capacity to improve drug supply in the sector. The merger aims to provide better access to essential injectable medications, significantly strengthening Juno's position in the specialty pharmaceutical sector. Omega Laboratories Inc. is a US-based drug testing laboratory that produce medications that support the management of conditions related to congenital diaphragmatic hernia.

Regional Insights

North America was the largest region in the congenital diaphragmatic hernia drugs market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Congenital Diaphragmatic Hernia Drugs Market?

The congenital diaphragmatic hernia drugs market consists of revenues earned by entities by providing surgical treatments and medical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital diaphragmatic hernia drug market also includes sales of pain management medications, antibiotics, vasoactive agents, dobutamine and milrinone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Congenital Diaphragmatic Hernia Drugs Market Report 2026?

The congenital diaphragmatic hernia drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the congenital diaphragmatic hernia drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.